Wu, Y., Li, Y., Zhang, P., Guo, S., Yuan, F., Liu, V., . . . Li, X. Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: A double-blind, randomized, placebo-controlled phase 2 trial. Nature Publishing Group.
Chicago Style (17th ed.) CitationWu, Yanling, et al. Inhaled Bispecific Single-domain Antibody BM219 for Mild-to-moderate COVID-19: A Double-blind, Randomized, Placebo-controlled Phase 2 Trial. Nature Publishing Group.
MLA (9th ed.) CitationWu, Yanling, et al. Inhaled Bispecific Single-domain Antibody BM219 for Mild-to-moderate COVID-19: A Double-blind, Randomized, Placebo-controlled Phase 2 Trial. Nature Publishing Group.
Warning: These citations may not always be 100% accurate.